Related Experiment Video
Updated: Oct 28, 2025
Using In Vitro Live-cell Imaging to Explore Chemotherapeutics Delivered by Lipid-based Nanoparticles
Published on: November 1, 2017
Lipid mediator lipoxin A4 and its analog BML-111 exert antitumor effects in melanoma
Yu Du1,2, Jianing Yang2,3, Tangfeng Su4
1Department of Anesthesiology, Sichuan Provincial People's Hospital, University of Electronic and Technology of China, Chengdu, China.
Background:
LipoxinA4 (LXA4) is an anti-inflammatory lipid mediator which was recently proposed to have antitumor potential. However, the therapeutic effect of LXA4 in melanoma is still unclear. This work aimed to investigate the function of LXA4 and its analog in melanoma invasion through in vivo and in vitro experiments.
Methods:
The expression of the LXA4 receptor (ALXR) was detected in melanoma tissues and A375 human melanoma cells, using benign melanocytic nevi tissues and human melanocytes as negative controls, respectively. The invasive and apoptotic abilities of A375 cells in the presence or absence of LXA4 were examined by cell invasion assay and flow cytometric analysis. Finally, mice melanoma models were established, and the antitumor effects of BML-111 [5(S), 6(R)-7-trihydroxymethyl heptanoate], an agonist of ALXR, were examined in vivo.
Results:
ALXR was abundantly expressed in human melanoma tissues. The ALXR messenger RNA (mRNA) and protein expression levels were higher in A375 melanoma cells than in the controls (P<0.05). LXA4 could significantly attenuate the invasion ability of A375 cells (P<0.05). This trend was further enhanced by BML-111, which tended to control the tumor development in A375 melanoma models.
Conclusions:
LXA4 and its analog BML-111 exert antitumor effects in vivo and in vitro, and may be potential therapeutic options for patients with invasive melanoma.
Insights
LipoxinA4 (LXA4) and its analog BML-111 show antitumor potential against melanoma. These compounds reduce melanoma cell invasion and tumor development, suggesting they may be effective therapeutic options for invasive melanoma patients.
Area of Science:
- Oncology
- Immunology
- Pharmacology
Background:
- LipoxinA4 (LXA4) is an anti-inflammatory mediator with potential antitumor properties, but its efficacy in melanoma remains under investigation.
- Melanoma invasion and development are complex processes influenced by various molecular mediators.
- Understanding the role of LXA4 and its analogs in melanoma is crucial for developing novel therapeutic strategies.
Purpose of the Study:
- To investigate the function of LipoxinA4 (LXA4) and its analog, BML-111, in melanoma invasion.
- To evaluate the therapeutic potential of LXA4 and BML-111 as antitumor agents in melanoma models.
Main Methods:
- Detection of the LXA4 receptor (ALXR) expression in melanoma tissues and cells.
- Assessment of melanoma cell invasion and apoptosis in response to LXA4.
- Evaluation of the antitumor effects of BML-111 in mice melanoma models.
Main Results:
- ALXR was highly expressed in human melanoma tissues and A375 melanoma cells.
- LXA4 significantly reduced the invasive capacity of A375 melanoma cells.
- BML-111 demonstrated a trend towards controlling tumor development in vivo.
Conclusions:
- LXA4 and its analog BML-111 exhibit significant antitumor effects in both in vitro and in vivo melanoma models.
- These findings suggest that LXA4 and BML-111 could represent promising therapeutic options for invasive melanoma.
More Related Videos
08:18Analysis of Lymph Node Volume by Ultra-High-Frequency Ultrasound Imaging in the Braf/Pten Genetically Engineered Mouse Model of Melanoma
Published on: September 8, 2021
09:15Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
Published on: February 24, 2023